GP96 C-terminal improves Her2/neu DNA vaccine

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• DNA vaccines targeting tumor antigens like Her2 show promise but are limited by self-tolerance.
• Strategies to enhance DNA vaccine efficacy include combining antigens with immune-stimulating molecules.
• GP96 is known to activate innate and adaptive immunity, particularly dendritic cells.

Purpose of the Study:

• To evaluate the immune response generated by fusing or co-administering the C-terminal of GP96 with Her2/neu DNA constructs.
• To determine if the C-terminal of GP96 can act as a molecular adjuvant to enhance anti-tumor immunity.

Main Methods:

• Constructs containing Her2/neu were fused or co-administered with the C-terminal of GP96.
• The resulting immune responses were evaluated and compared in experimental models.

Main Results:

• Fusion of Her2/neu with the C-terminal of GP96 significantly reduced regulatory T cells at the tumor site.
• This fusion construct enhanced cytotoxic T lymphocyte activity and increased interferon-gamma secretion.
• Co-administration of separate constructs did not yield the same beneficial immune effects.

Conclusions:

• The C-terminal of GP96 exhibits potent adjuvant activity when fused with Her2/neu.
• This fusion strategy effectively elicits a significant anti-tumor immune response.
• The C-terminal of GP96 holds potential as a molecular adjuvant for various antigens.